MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Alcon Inc

Gesloten

SectorGezondheidszorg

89.7 -2.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

89.26

Max

92.53

Belangrijke statistieken

By Trading Economics

Inkomsten

21M

284M

Verkoop

48M

2.5B

K/W

Sectorgemiddelde

46.307

63.778

EPS

0.72

Dividendrendement

0.28

Winstmarge

11.351

Werknemers

25,599

EBITDA

56M

397M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+15.91% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.28%

2.39%

Volgende Winsten

13 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

5.9B

47B

Vorige openingsprijs

92.56

Vorige sluitingsprijs

89.7

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Alcon Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mrt 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24 mrt 2025, 12:36 UTC

Acquisities, Fusies, Overnames

Alcon to Buy Lensar in Deal Worth Up to $430 Million

12 nov 2024, 18:48 UTC

Winsten
Belangrijke Marktbewegers

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

26 mrt 2025, 21:55 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mrt 2025, 20:33 UTC

Acquisities, Fusies, Overnames

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mrt 2025, 20:32 UTC

Acquisities, Fusies, Overnames

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mrt 2025, 20:32 UTC

Acquisities, Fusies, Overnames

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mrt 2025, 20:31 UTC

Acquisities, Fusies, Overnames

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26 mrt 2025, 20:31 UTC

Acquisities, Fusies, Overnames

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26 mrt 2025, 20:31 UTC

Acquisities, Fusies, Overnames

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26 mrt 2025, 20:30 UTC

Acquisities, Fusies, Overnames

Alcon Acquires Majority Interest in Aurion Biotech

24 mrt 2025, 12:21 UTC

Acquisities, Fusies, Overnames

Alcon to Buy Lensar in Deal Worth Up to $430M

24 mrt 2025, 12:05 UTC

Acquisities, Fusies, Overnames

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24 mrt 2025, 12:05 UTC

Acquisities, Fusies, Overnames

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24 mrt 2025, 12:04 UTC

Acquisities, Fusies, Overnames

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24 mrt 2025, 12:04 UTC

Acquisities, Fusies, Overnames

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24 mrt 2025, 12:03 UTC

Acquisities, Fusies, Overnames

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24 mrt 2025, 12:03 UTC

Acquisities, Fusies, Overnames

Alcon Agrees to Acquire LENSAR >ALC

24 mrt 2025, 12:00 UTC

Acquisities, Fusies, Overnames

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25 feb 2025, 21:33 UTC

Winsten

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25 feb 2025, 21:33 UTC

Winsten

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25 feb 2025, 21:32 UTC

Winsten

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25 feb 2025, 21:31 UTC

Winsten

Alcon 4Q EPS 57c >ALC.EB

25 feb 2025, 21:31 UTC

Winsten

Alcon 4Q Rev $2.5B >ALC.EB

17 dec 2024, 15:05 UTC

Marktinformatie

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

12 nov 2024, 17:38 UTC

Winsten

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

12 nov 2024, 17:38 UTC

Winsten

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

12 nov 2024, 17:37 UTC

Winsten

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

12 nov 2024, 17:36 UTC

Winsten

Alcon 3Q Core Operating Margin 20.6% >ALC

12 nov 2024, 17:36 UTC

Winsten

Alcon 3Q Sales $2.43B >ALC

Peer Vergelijking

Prijswijziging

Alcon Inc Prognose

Koersdoel

By TipRanks

15.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.45 USD  15.91%

Hoogste 120 USD

Laagste 90 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alcon Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

18

Buy

2

Hold

0

Sell

Technische score

By Trading Central

90.87 / 92.61Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.